USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ACRYMED, INC.
City: BEAVERTON
State: OR
Zip+4: 97008
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (503) 624-9830

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $528,204.00 5
SBIR Phase II $1,043,479.00 2
STTR Phase I $130,453.00 1

Award List:

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce L. Gibbins
Award Amount: $130,807.00

On demand antimicrobial iodine in a wound contact matrix

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce L. Gibbins
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): Wound infection is the single-most important complication encountered in the management of chronic non-healing wounds. More than 10 million US patients per annum, at a cost of greater than $10 billion, receive treatment for chronic… More

On demand antimicrobial iodine in a wound contact matrix

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: Bruce L. Gibbins
Award Amount: $347,380.00
Abstract:
DESCRIPTION (provided by applicant): Wound infection is the single-most important complication encountered in the management of chronic non-healing wounds. More than 10 million US patients per annum, at a cost of greater than $10 billion, receive treatment for chronic… More

ENTRAPMENT OF 02 IN A SEMI-SOLID FOR HYPOXIC WOUNDS

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce L. Gibbins
Award Amount: $120,305.00
Abstract:
DESCRIPTION (Verbatim from the Applicant's Abstract): More than 15 million patients in the US alone suffer from recalcitrant non-healing wounds with an estimated expenditure of greater than $10 billion in treatment costs. The demographic shift in longevity will mean an… More

NOVEL ANTIMICROBIAL TREATMENT IN BURN GRAFT BIOMATERIALS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce L. Gibbins
Award Amount: $133,386.00
Abstract:
Collagen based biosynthetic materials have profoundly improved the outcome of reconstruction and restoration of congenital defects and traumatic injuries. This has been most apparent for massive burn victims that historically suffered lifelong severe scarring and lost of function following wound… More

Novel Antimicrobial Treatment in Burn Graft Biomaterials

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Bruce L. Gibbins
Award Amount: $696,099.00
Abstract:
DESCRIPTION (provided by applicant): Burn injuries represent the most terrifying and horrific trauma imaginable. This image is conditioned, in part, from the appearance of surviving bum victims that have been horribly scarred and disfigured following the healing of their injuries. Fortunately… More

Silver coatings to combat catheter associated infections

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce Gibbins
Award Amount: $143,706.00
Abstract:
DESCRIPTION (provided by applicant): Abstract Indwelling catheterization is a leading cause of nosocomial infections that present an enormous drain of health care funding in the US. Clinical infections associated with urinary catheterization have been estimated to add more than $1000 to patient… More

Retinoids as Novel Treatment of Ischemic Stroke

Award Year / Program / Phase: 2006 / STTR / Phase I
Agency: HHS
Research Institution: OREGON HEALTH & SCIENCE UNIVERSITY
Principal Investigator: Jeanbaptiste O. Roullet
Award Amount: $130,453.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Stroke is the third leading cause of death in the U.S. and a major source of disability. Ischemic stroke, the most common type, is associated with a dramatic increase in calcium influx in brain tissue, an increased production in reactive oxygen species (ROS),… More